Cytokinetics Inc
NASDAQ:CYTK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
44.6
108.06
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Cytokinetics Inc
Wall Street
Price Targets
CYTK Price Targets Summary
Cytokinetics Inc
According to Wall Street analysts, the average 1-year price target for
CYTK
is 85.14 USD
with a low forecast of 60.6 USD and a high forecast of 126 USD.
CYTK Last Price Targets
Cytokinetics Inc
The latest public price target was made on Oct 17, 2024 by
Joseph Pantginis
from
H.C. Wainwright
,
who expects
CYTK
stock to
rise by 146%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Joseph Pantginis
H.C. Wainwright
|
120
USD
Upside 146% |
2 months ago
Oct 17, 2024
|
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
StreetInsider
|
Paul Choi
Goldman Sachs
|
60
USD
Upside 23% |
3 months ago
Sep 3, 2024
|
Goldman Sachs Reiterates Neutral Rating on Cytokinetics (CYTK)
StreetInsider
|
Yasmeen Rahimi
Piper Sandler
|
107
USD
Upside 119% |
6 months ago
Jun 10, 2024
|
Piper Sandler Reiterates Overweight Rating on Cytokinetics (CYTK)
StreetInsider
|
|
Mayank Mamtani
B.Riley Financial
|
92
USD
Upside 88% |
6 months ago
Jun 4, 2024
|
Cytokinetics (CYTK) PT Lowered to $92 at B.Riley
StreetInsider
|
Jason Butler
JMP Securities
|
78
USD
Upside 60% |
6 months ago
May 28, 2024
|
Cytokinetics price target lowered to $78 from $106 at JMP Securities
TheFly
|
Carter Gould
Barclays
|
95
USD
Upside 94% |
7 months ago
May 23, 2024
|
Cytokinetics price target lowered to $95 from $100 at Barclays
TheFly
|
|
Joseph Pantginis
H.C. Wainwright
|
90
USD
Upside 84% |
7 months ago
May 23, 2024
|
Cytokinetics price target lowered to $90 from $94 at H.C. Wainwright
TheFly
|
Serge Belanger
Needham
|
72
USD
Upside 47% |
7 months ago
May 23, 2024
|
Cytokinetics price target lowered to $72 from $108 at Needham
TheFly
|
Akash Tewari
Jefferies
|
85
USD
Upside 74% |
7 months ago
May 23, 2024
|
Cytokinetics (CYTK) PT Lowered to $85 at Jefferies
StreetInsider
|
|
Jason Butler
JMP Securities
|
106
USD
Upside 117% |
7 months ago
May 9, 2024
|
Cytokinetics price target lowered to $106 from $110 at JMP Securities
TheFly
|
Justin Kim
Oppenheimer
|
106
USD
Upside 117% |
7 months ago
May 9, 2024
|
Cytokinetics price target lowered to $106 from $107 at Oppenheimer
TheFly
|
Salim Syed
Mizuho Securities
|
99
USD
Upside 103% |
8 months ago
Apr 5, 2024
|
Mizuho on Cytokinetics (CYTK) Presentation: 'OREST oHCM 48wk Data @ ACC '24 ==> Incremental +ive'
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is CYTK's stock price target?
Price Target
85.14
USD
According to Wall Street analysts, the average 1-year price target for
CYTK
is 85.14 USD
with a low forecast of 60.6 USD and a high forecast of 126 USD.
What is Cytokinetics Inc's Revenue forecast?
Projected CAGR
222%
For the last 8 years the
compound annual growth rate for
Cytokinetics Inc's revenue is
-15%.
The projected
CAGR
for the next 4 years is
222%.
You don't have any saved screeners yet
